Skip to main content
Download PDF
Download ePub

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery volume 19, Article number: 421 (2024) Cite this article

Abstract

Background

Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.

Methods

PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of durvalumab supplementation on efficacy in patients with NSCLC. Overall survival and progression-free survival were included for this meta-analysis.

Results

Four RCTs were finally included in the meta-analysis. Overall, compared with control group for NSCLC, durvalumab supplementation showed significantly improved survival rate (odd ratio [OR] = 1.64; 95% confidence interval [CI] = 1.31 to 2.06; P < 0.0001), overall survival ( hazard ratio [HR] = 0.73; 95% CI = 0.61 to 0.87; P = 0.0003), progression-free survival rate (OR = 2.31; 95% CI = 1.78 to 3.01; P < 0.00001) and progression-free survival (HR = 0.71; 95% CI = 0.54 to 0.95; P = 0.02), and had the capability to reduce the incidence of grade ≥ 3 adverse events (OR = 0.26; 95% CI = 0.16 to 0.42; P < 0.00001).

Conclusions

Durvalumab supplementation is effective to improve the efficacy for NSCLC.

Peer Review reports

Introduction

Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or its ligand programmed cell death ligand-1 (PD-L1) have important potential in treating non-small-cell lung cancer (NSCLC) [1,2,3,4,5]. However, not all patients with NSCLC can obtain immunotherapy in the first- or second-line setting because of many factors including approval/availability of these products at that time in some countries [6]. More therapy options are needed for patients with disease progression.

As one selective, high-affinity, human immuno-globulin G1 monoclonal antibody, durvalumab has shown the promise for the treatment of patients with unresectable, stage III NSCLC by blocking PD-L1 binding to PD-1 and CD80 [7, 8]. Especially, in patients with PD-L1 expression levels, anti-PD-1/PD-L1 monotherapies was reported to significantly improve the efficacy outcomes of lung cancers [9,10,11].

Several RCTs showed that durvalumab supplementation may have the capability to improve the efficacy for NSCLC, but the results were not well established [6, 8, 12]. Considering these inconsistent effects, we therefore conducted a systematic review and meta-analysis of RCTs to evaluate the effectiveness of durvalumab supplementation versus standard chemotherapy on treatment efficacy for NSCLC.

Materials and methods

Study selection and data collection

This meta-analysis of previously studies did not need ethical approval or patient consent. It was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement and Cochrane Handbook for Systematic Reviews of Interventions [13, 14].

We have searched PubMed, EMbase, Web of science, EBSCO, and the Cochrane library up to June 2022, using the search terms “durvalumab” AND “lung cancer” OR “NSCLC”. The inclusion criteria were as follows: (1) study design was RCT; (2) patients were diagnosed with NSCLC; (3) intervention treatments were durvalumab versus standard chemotherapy.

Assessment for risk of bias

The risk of bias tool was used to assess the quality of individual studies in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [15], and the following sources of bias were considered: selection bias, performance bias, attrition bias, detection bias, reporting bias, and other potential sources of bias. The overall risk of bias for each study was evaluated and rated: low, when the risk of bias was low in all key domains; unclear, when the risk of bias was low or unclear in all key domains; and high, when the risk of bias was high in one or more key domains [16]. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. Any discrepancy was solved by consensus.

Outcome measures

The following information was extracted: first author, publication year, sample size, age, male, tumor histologic subtype (squamous/nonsquamous) and methods of two groups. The primary outcomes were survival rate and overall survival. Secondary outcomes included progression-free survival rate, progression-free survival, adverse events, and grade ≥ 3 adverse events.

Statistical analysis

A team consisting of three authors did the statistical analyses. Hazard ratio (HR) with 95% confidence interval (CI) was used to assess continuous outcomes and odd ratio (OR) with 95% CI was used to assess dichotomous outcomes. I2 statistic was used to assess the heterogeneity, and significant heterogeneity was observed when I2 > 50% [17]. The random-effect model was used regardless of the heterogeneity. We conducted the sensitivity analysis through detecting the influence of a single study on the overall estimate via omitting one study in turn or using the subgroup analysis. P< 0.05 indicated statistical significance and Review Manager Version 5.3 was used in all statistical analyses.

Results

Literature search, study characteristics and quality assessment

The flow chart for the selection process and detailed identification was presented in Fig. 1. 385 publications were identified through the initial search of databases. Ultimately, four RCTs were included in the meta-analysis [6, 8, 12, 18].

Fig. 1
figure 1

Flow diagram of study searching and selection process

Full size image

The baseline characteristics of the four eligible RCTs in the meta-analysis were summarized in Table 1. The four studies were published between 2017 and 2020, and total sample size was 1399. There were similar baseline characteristics between durvalumab group and control group. The treatment duration of durvalumab supplement were different in each RCT, ranging from 2 years to 3 years. Two studies reported the same patient sample with different outcomes [8, 18].

Table 1 Characteristics of included studies
Full size table

Among the four RCTs, three studies reported survival rate and overall survival [6, 8, 12], three studies reported progression-free survival rate and progression-free survival [6, 12, 18], as well as two studies reported adverse events, grade ≥ 3 adverse events and adverse events [6, 12]. Risk of bias analysis (Fig. 2) showed that two studies had high risk of performance bias and detection bias due to the open label of two groups [6, 12], but all RCTs generally had high quality.

Fig. 2
figure 2

Risk of bias assessment. (A) Authors’ judgments about each risk of bias item for each included study. (B) Authors’ judgments about each risk of bias item presented as percentages across all included studies

Full size image

Primary outcomes: survival rate and overall survival

Compared to control group for NSCLC, durvalumab supplementation was associated with significantly higher survival rate (OR = 1.64; 95% CI = 1.31 to 2.06; P < 0.0001) with no heterogeneity among the studies (I2 = 0%, heterogeneity P = 0.40, Fig. 3) and prolonged overall survival (HR = 0.73; 95% CI = 0.61 to 0.87; P = 0.0003) with no heterogeneity among the studies (I2 = 0%, heterogeneity P = 0.79, Fig. 4).

Fig. 3
figure 3

Forest plot for the meta-analysis of survival rate

Full size image
Fig. 4
figure 4

Forest plot for the meta-analysis of overall survival

Full size image

Sensitivity analysis

No heterogeneity was observed for the primary outcomes, and thus we did not perform the sensitivity analysis by omitting one study in turn for the meta-analysis.

Secondary outcomes

Compared with control group for NSCLC, durvalumab supplementation showed substantially improved progression-free survival rate (OR = 2.31; 95% CI = 1.78 to 3.01; P < 0.00001; Fig. 5) and progression-free survival (HR = 0.71; 95% CI = 0.54 to 0.95; P = 0.02; Fig. 6). With regard to the safety, durvalumab supplementation showed no obvious impact on the incidence of adverse events (OR = 0.50; 95% CI = 0.15 to 1.66; P = 0.26; Fig. 7), but was associated with substantially reduced grade ≥ 3 adverse events (OR = 0.26; 95% CI = 0.16 to 0.42; P < 0.00001; Fig. 8).

Fig. 5
figure 5

Forest plot for the meta-analysis of progression-free survival rate

Full size image
Fig. 6
figure 6

Forest plot for the meta-analysis of progression-free survival

Full size image
Fig. 7
figure 7

Forest plot for the meta-analysis of adverse events

Full size image
Fig. 8
figure 8

Forest plot for the meta-analysis of grade ≥ 3 adverse events

Full size image

Discussion

In the phase II ATLANTIC trial, durvalumab showed important potential in improving the efficacy for heavily pretreated (third-line or higher) patients with NSCLC when compared with other anti-PD-1/PD-L1 agents [2]. Durvalumab has become an increasingly important immunoglobulin G1 monoclonal antibody to block PD-L1. In order to explore the efficacy of durvalumab supplementation for NSCLC patients, our meta-analysis included four RCTs and 1399 patients. The results suggested that compared to control intervention, durvalumab supplementation substantially benefited to improve survival rate, overall survival, progression-free survival rate and progression-free survival for patients with NSCLC.

In terms of sensitivity analysis, although there was no significant heterogeneity, several factors may produce some bias. Firstly, the stages of NSCLC were different among included RCTs, including metastatic and locally advanced cancers. Squamous and nonsquamous histologic types were both included, and they may have various sensitivity to durvalumab treatment. Thirdly, the treatment duration of durvalumab supplementation varied from 2 years to 3 years, which may affect the efficacy assessment. Indeed, anti-PD-1/PD-L1 therapies have demonstrated clinical benefit in patients with various PD-L1 expression levels, even in those with PD-L1-negative tumors [2, 19]. Additionally, the simultaneous blockade of the PD-1/PD-L1 and cytotoxic T lymphocyte-associated antigen-4 pathways were confirmed to produce additive or synergistic antitumor activity and may be an important treatment option in patients with low/negative PD-L1 expression [20,21,22].

With regards to the safety, durvalumab supplementation led to similar incidence of adverse events compared to standard chemotherapy, but can remarkably reduce the incidence of grade ≥ 3 adverse events for NSCLC patients. We should also consider several limitations. Firstly, our analysis was based on only four RCTs and more studies with large patient samples should be conducted to confirm this finding. Secondly, the duration of durvalumab treatment were different in the included studies, and may mainly account for some heterogeneity. Thirdly, NSCLC patients with different stages may produce some bias for efficacy assessment.

Conclusion

Durvalumab supplementation showed improved treatment efficacy for NSCLC patients with reduced incidence of grade ≥ 3 adverse events.

Data availability

Not applicable.

References

  1. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr., Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (London England). 2019;393(10183):1819–30.

    Article  CAS  PubMed  Google Scholar 

  2. Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study, the Lancet. Oncology. 2018;19(4):521–36.

    CAS  PubMed  Google Scholar 

  3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Perez BA, Boothman AM, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Faivre-Finn, outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(6):798–806.

    Article  CAS  Google Scholar 

  5. Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study, the Lancet. Oncology. 2019;20(12):1670–80.

    CAS  PubMed  Google Scholar 

  6. Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(5):609–18.

    Article  CAS  Google Scholar 

  7. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.

    Article  CAS  PubMed  Google Scholar 

  8. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro J, Carpeño C, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada PA, Dennis M, Özgüroğlu Ö. Overall survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.

    Article  CAS  PubMed  Google Scholar 

  9. Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol/Hematol. 2016;101:75–85.

    Article  PubMed  Google Scholar 

  10. Zhou GW, Xiong Y, Chen S, Xia F, Li Q, Hu J. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: a meta-analysis of randomized clinical trials. Medicine. 2016;95(35):e4611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH. Clinical activity, tolerability, and Long-Term Follow-Up of Durvalumab in patients with Advanced NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(10):1794–806.

    Article  CAS  Google Scholar 

  12. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S. Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-line treatment of metastatic non-small cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):661–74.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.

  15. Higgins GS. JPT, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration (2011). www.cochrane-handbook.org.

  16. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. Cochrane Bias methods, G. Cochrane Statistical methods, the Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  18. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M. Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  PubMed  Google Scholar 

  19. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor expression of programmed death-Ligand-1 (PD-L1): sensitivity analysis of trials in Melanoma, Lung and Genitourinary cancers. PLoS ONE. 2015;10(6):e0130142.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus Ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, the Lancet. Oncology. 2017;18(1):31–41.

    CAS  PubMed  Google Scholar 

  21. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F. Paz-Ares, Nivolumab plus Ipilimumab in Lung Cancer with a high Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial, the Lancet. Oncology. 2021;22(1):51–65.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

Not applicable.

Author information

Author notes

  1. Chengchen Wang and Hongyi Fu contributed equally to this study.

Authors and Affiliations

  1. Department of Oncology Radiotherapy Center, Chongqing University Cancer Hospital, Chongqing, 400030, China

    Chengchen Wang & Feng Wang

  2. Department of Nursing, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China

    Hongyi Fu

  3. Chongqing University Cancer Hospital, No. 181 Hanyu Road, Chongqing, 400030, China

    Chengchen Wang

Authors
  1. Chengchen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongyi Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Chengchen Wang and Feng Wang conducted the design, study planning, data analysis and data interpretation. Hongyi Fu wrote and revised the article. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chengchen Wang.

Ethics declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Fu, H. & Wang, F. Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study. J Cardiothorac Surg 19, 421 (2024). https://doi.org/10.1186/s13019-024-02940-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13019-024-02940-3

Keywords

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us